Report Fraud About Us What We Do

Consumer News

Calcilo XD Infant Formula Recalled Due to ‘Inconsistency’ Says FDA Notice

The FDA issued a recall notice for infant formula by Abbott Laboratories who “out of an abundance of caution,” has “voluntarily recalled a single lot of Calcilo XD® powder cans” due to what the company calls “an inconsistency in aroma and color.”

The inconsistency recall affects “a small number of cans from this specific batch” of the product in the United States and Canada in the 13.2oz (375g) with lot number 79696K80.

Image: FDA

The recall notice for this lot of products says no other lots of Calcilo XD, or any other Abbott products are affected. Abbot assures consumers their “products can continue to be used with confidence.”

Consumers who purchased Calcilo XD® powder cans should cease using the product and contact Abbott Laboratories for instructions on how and where to return the product by calling 800-850-7677 in the United States and 855-733-4201 in Canada.

Do you have additional information about this recall? Is there another recall you want us to cover? Tell us in the comments below. You can also contact us for more information! Feel free to shoot us an email to Outreach@ConsiderTheConsumer.com. You can also find us on TwitterFacebook, InstagramLinkedIn, or even connect with us directly on our website!

About the Author: Aisha K. Staggers is a writer, lecturer, political analyst and literary agent. She appears weekly for “Staggers’ State of Things” on the Dr. Vibe Show. Her work has been published by Paper Magazine, AfroPunk, The Spool, GREY Journal, MTV News, HuffPost, Blavity, Atlanta Blackstar, For Harriet, New York Review of Books and a host of other first-run publications and syndicated outlets. Find her on Twitter @AishaStaggers. For more of her work, check out her page here!

Interested in posts like these? Stay up to date with our newsletter!

No thoughts on “Calcilo XD Infant Formula Recalled Due to ‘Inconsistency’ Says FDA Notice” yet. Be the first to speak your mind!

Leave a Reply